帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好，仅出现轻度胃肠道不良事件，并展现出有前景的活性，值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/转移性头颈部鳞状细胞癌中 TIL（肿瘤浸润淋巴细胞）与 PD-L1 的联合状态
英文原题：Combined Tumor Infiltrating Lymphocytes and PD-L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
查看英文原题
Combined Tumor Infiltrating Lymphocytes and PD-L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在 R/M HNSCC 中，PD-L1 CPS 与 CD8+ TILs 的联合使用，相较于单独使用任一生物标志物，是更强的总生存期预后生物标志物。
研究思路结论见上方概要
目的
确定CD8+TIL（肿瘤浸润淋巴细胞）（TILs）的评估是否能为复发/转移性（R/M）头颈部鳞状细胞癌（HNSCC）中的PD-L1联合阳性评分（CPS）提供额外的预后信息。
方法
对2003年至2019年间77例R/M HNSCC患者进行了回顾性病例系列研究。通过治疗前活检，在组织芯片上对CD8+ TILs和PD-L1 CPS进行了定量。评估了生物标志物与总生存期及免疫检查点抑制（ICI）缓解之间的关联。
结果
CD8+ TIL计数或PD-L1 CPS单独均与总生存期无关；然而，TILs高且CPS 1联合与TILs低且CPS < 1相比，与生存改善相关（18.5 vs. 10.0个月，p = 0.058）。对于接受ICI治疗的患者（n = 28），PD-L1 CPS对ICI反应的预测强于CD8+ TILs。
展开英文摘要原文
OBJECTIVES
To determine if the assessment of CD8+ tumor-infiltrating lymphocytes (TILs) adds prognostic information to the PD-L1 combined positive score (CPS) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
METHODS
A retrospective case series was performed of 77 patients with R/M HNSCC between 2003 and 2019. From pre-treatment biopsies, CD8+ TILs and PD-L1 CPS were quantified on a tissue microarray. Associations of biomarkers with overall survival and immune checkpoint inhibition (ICI) response were assessed.
RESULTS
Neither CD8+ TIL counts nor PD-L1 CPS alone were associated with overall survival; however, combined high TILs and CPS 1 were associated with improved survival compared to low TILS and CPS < 1 (18.5 vs. 10.0 months, p = 0.058). For patients treated with ICI (n = 28), PD-L1 CPS predicted ICI response more strongly than CD8+ TILs.
CONCLUSIONS
In R/M HNSCC, the combination of PD-L1 CPS and CD8+ TILs is a stronger prognostic biomarker for overall survival compared with either biomarker alone.
论文信息
- 作者
- Haring CT、Smith JD、Dermody SM、McHugh JB、Perry WR、Brummel C、Spector ME、Brenner JC
- 第一作者单位
- Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, Ohio, USA.United States
- 通讯作者单位
- Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA.United States
- 文献类型
- 美国 NIH 资助研究
- 期刊
- Head & neck2025 Aug
- 原文标识
- PubMed 40045701 · DOI 10.1002/hed.28128
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →